Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Mallinckrodt
Express Scripts
Chinese Patent Office
Chubb
McKinsey
Citi
Merck
Queensland Health
Healthtrust

Generated: October 24, 2017

DrugPatentWatch Database Preview

Hydroxocobalamin - Generic Drug Details

« Back to Dashboard

What are the generic sources for hydroxocobalamin and what is the scope of hydroxocobalamin patent protection?

Hydroxocobalamin
is the generic ingredient in four branded drugs marketed by Abraxis Pharm, Watson Labs, Bel Mar, Serb Sa, Merck, and Actavis Llc, and is included in six NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Hydroxocobalamin has thirteen patent family members in nine countries.

There are four drug master file entries for hydroxocobalamin. Two suppliers are listed for this compound.

Summary for Generic Name: hydroxocobalamin

US Patents:1
Tradenames:4
Applicants:6
NDAs:6
Drug Master File Entries: see list4
Suppliers / Packagers: see list2
Clinical Trials: see list2
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:hydroxocobalamin at DailyMed

Pharmacology for Ingredient: hydroxocobalamin

Drug ClassAntidote
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Pharm
HYDROXOCOBALAMIN
hydroxocobalamin
INJECTABLE;INJECTION084921-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Serb Sa
CYANOKIT
hydroxocobalamin
INJECTABLE;INJECTION022041-002Dec 15, 2006DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Actavis Llc
HYDROXOCOBALAMIN
hydroxocobalamin
INJECTABLE;INJECTION085998-001Approved Prior to Jan 1, 1982RXNoYes► Subscribe► Subscribe► Subscribe
Bel Mar
HYDROXOMIN
hydroxocobalamin
INJECTABLE;INJECTION084629-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Serb Sa
CYANOKIT
hydroxocobalamin
INJECTABLE;INJECTION022041-001Apr 8, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Watson Labs
HYDROXOCOBALAMIN
hydroxocobalamin
INJECTABLE;INJECTION085528-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Merck
ALPHAREDISOL
hydroxocobalamin
INJECTABLE;INJECTION080778-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: hydroxocobalamin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Serb Sa
CYANOKIT
hydroxocobalamin
INJECTABLE;INJECTION022041-002Dec 15, 2006► Subscribe► Subscribe
Serb Sa
CYANOKIT
hydroxocobalamin
INJECTABLE;INJECTION022041-001Apr 8, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: hydroxocobalamin

Country Document Number Estimated Expiration
France2740973► Subscribe
Australia7172096► Subscribe
Germany69619767► Subscribe
Iceland4387► Subscribe
European Patent Office0775485► Subscribe
Australia720219► Subscribe
JapanH09136837► Subscribe
Iceland1880► Subscribe
Japan3699223► Subscribe
Denmark0775485► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Cerilliant
Dow
Mallinckrodt
Medtronic
US Department of Justice
Cantor Fitzgerald
Chinese Patent Office
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot